About xCella
xCella is a Healthcare company based in Menlo Park (United States) founded in 2016 by Bob Chen, and was acquired by Ligand Pharmaceuticals in September 2020. Developer of immuno-oncology antibody therapeutics. The company was acqui-hired. xCella offers products and services including OmniRat, OmniMouse, OmniChicken, and Omni dAb. Its focus areas include Life Sciences, Immunotherapy, Antibody and Immunomodulatory. Its legal entity is OmniAb, Inc. Its competitors include Avidity Biosciences, PureTech Health and Sutro Biopharma; 3 of its 3 listed competitors have raised funding.
Company details
xCella was founded in 2016 and is based in Menlo Park, United States, within the biotechnology sector. Immuno-oncology antibody therapeutics are developed through the proprietary xEmplar human antibody library and xPloration functional screening technology. A pipeline targeting difficult molecules is constructed, with emphasis placed on immunomodulatory agents such as receptor agonists, G-protein coupled receptor modulators, and enzyme inhibitors. Operations center on advancing these therapeutics for oncology applications.
- Headquarters Menlo Park, United States
- Founders Bob Chen
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website xcellabio.com
- Social LinkedIn X
- Acquired by Ligand Pharmaceuticals (Sep 2020)
- Legal Name Omniab, Inc.
- Investors
- Acquired byLigand Pharmaceuticals
(Sep 2020)
Products & Services of xCella
xCella offers a comprehensive portfolio of products and services, including OmniRat, OmniMouse, OmniChicken, and Omni dAb.
Transgenic rat platform for human antibody production.
Transgenic mouse system for antibody discovery.
Transgenic chicken host for single-domain antibodies.
Platform for humanized single-domain antibody development.
Investors in xCella
xCella has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ligand Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical drugs are manufactured and developed in the United States. | 1987 | ligand.com | San Diego, United States |
Investor details for xCella
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of xCella
1 people are tracked at xCella (1 in leadership).
| Name | Role | Group |
|---|---|---|
Bob Chen | Co-Founder | Leadership |
Complete people profiles for xCella
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of xCella
2 dated milestones of xCella across 4 years, from founding to its latest funding, stage changes and deals.
- Founded xCella is founded.
- Exit Acquired by Ligand Pharmaceuticals.
Competitors of xCella
xCella has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, PureTech Health and Sutro Biopharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. |
Detailed competitors of xCella
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as xCella (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Xcella
Complete news archive for xCella
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about xCella
xCella was founded in 2016.
xCella is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
xCella was founded in 2016 and is based in Menlo Park, United States, within the biotechnology sector. Immuno-oncology antibody therapeutics are developed through the proprietary xEmplar human antibody library and xPloration functional screening technology. A pipeline targeting difficult molecules is constructed, with emphasis placed on immunomodulatory agents such as receptor agonists, G-protein coupled receptor modulators, and enzyme inhibitors. Operations center on advancing these therapeutics for oncology applications.
xCella's top competitors include Sutro Biopharma, Avidity Biosciences and PureTech Health.
xCella offers OmniRat, OmniMouse, OmniChicken, and Omni dAb.
xCella has 1 investor. Key investors include Ligand Pharmaceuticals.
xCella operates through Omniab, Inc..
Yes. xCella was acquired by Ligand Pharmaceuticals in September 2020.